Sunshine Biopharma, Inc.

NasdaqCM:SBFM Stock Report

Market Cap: US$1.2m

Sunshine Biopharma Management

Management criteria checks 2/4

Sunshine Biopharma's CEO is Steve Slilaty, appointed in Oct 2009, has a tenure of 14.5 years. total yearly compensation is $430.00K, comprised of 83.7% salary and 16.3% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $1.41K. The average tenure of the management team and the board of directors is 0.3 years and 2.5 years respectively.

Key information

Steve Slilaty

Chief executive officer

US$430.0k

Total compensation

CEO salary percentage83.7%
CEO tenure14.5yrs
CEO ownership0.1%
Management average tenureless than a year
Board average tenure2.5yrs

Recent management updates

Recent updates

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Mar 14
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Jan 29
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sep 12
Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sunshine Biopharma acquires Nora Pharma for C$30M

Oct 20

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Aug 08
We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Sunshine Biopharma reports 1H results

Aug 04

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Apr 17

CEO Compensation Analysis

How has Steve Slilaty's remuneration changed compared to Sunshine Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$5m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$430kUS$360k

-US$27m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$5m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$462kUS$156k

-US$12m

Sep 30 2021n/an/a

-US$14m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$227kUS$177k

-US$3m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$972k

Dec 31 2019US$96kUS$28k

-US$1m

Sep 30 2019n/an/a

-US$1m

Jun 30 2019n/an/a

-US$2m

Mar 31 2019n/an/a

-US$2m

Dec 31 2018US$285kUS$85k

-US$2m

Sep 30 2018n/an/a

-US$2m

Jun 30 2018n/an/a

-US$1m

Mar 31 2018n/an/a

-US$1m

Dec 31 2017US$268kUS$156k

-US$1m

Compensation vs Market: Steve's total compensation ($USD430.00K) is below average for companies of similar size in the US market ($USD677.87K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Slilaty (71 yo)

14.5yrs

Tenure

US$430,000

Compensation

Dr. Steve N. Slilaty, Ph D., serves as the President, Chief Executive Officer and Chief Scientific Officer of Advanomics Corporation since February 2002. Dr. Slilaty serves as the Chairman, Chief Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Camille Sebaaly
CFO & Secretary14.5yrsUS$695.00k0.18%
$ 2.1k
Abderrazzak Merzouki
Chief Science Officer & Directorless than a yearUS$340.00k0.12%
$ 1.4k
Steve Slilaty
CEO, President & Chairman14.5yrsUS$430.00k0.12%
$ 1.4k
Marc Beaudoin
Chief Operating Officerless than a yearno datano data
Malek Chamoun
Chief Development Officerless than a yearno data3.72%
$ 44.8k
Robert Ferreira
President of Sunshine Bio Investments Incno datano datano data

0.3yrs

Average Tenure

60yo

Average Age

Experienced Management: SBFM's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Abderrazzak Merzouki
Chief Science Officer & Director8.2yrsUS$340.00k0.12%
$ 1.4k
Steve Slilaty
CEO, President & Chairman14.5yrsUS$430.00k0.12%
$ 1.4k
David Natan
Independent Director2.2yrsUS$80.00kno data
Rabi Kiderchah
Independent Director2.5yrsUS$80.00k0.0016%
$ 19.4
Andrew Keller
Independent Director2.2yrsUS$80.00kno data

2.5yrs

Average Tenure

69yo

Average Age

Experienced Board: SBFM's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.